Connecting to LinkedIn...

W1siziisijiwmtuvmdqvmtuvmdgvntqvmzgvnzi1l01ptlrbu0hfqkxpr19vtljftkrfukvex0lnqudfx3jlc2l6zwrfyw5kx3jlbmrlcmvklmpwzyjdlfsiccisinrodw1iiiwimtkymhgxmjuwiyjdxq

Blog

Convergence considers IPO after GSK spin-off, as European biotech revives

16/06/2014 by

W1siziisijiwmtqvmtavmjgvmtuvmzcvmzqvnjqvzmlszsjdlfsiccisinrodw1iiiwinjawedqwmfx1mdazzsjdxq

Convergence Pharmaceuticals, a specialist pain drug company spun off from GlaxoSmithKline, is preparing for a possible stock market listing as British biotech companies enjoy a revival of interest from investors.

The European sector has been slow to catch up with its U.S. peers, which have seen a renaissance in the past two years, but since allergy drug developer Circassia raised 200 million pounds ($335 million) in March – the biggest London market debut in years for a biotech company – the wider industry’s fortunes have turned.

Now Convergence Pharmaceuticals, which was created in 2010 following GSK’s decision to exit certain areas of neuroscience, says it could raise between 50 million and 100 million pounds in another substantial initial public offering.

Chief Executive Clive Dix said on Monday that listings in London and New York were under consideration, with a potential flotation most likely to take place early next year as the group readies its most advanced drug for final-stage clinical testing.

“We are now starting to talk to advisers about the state of the FTSE and Nasdaq markets for biotech and are considering seriously floating the company,” Dix said in an interview. “We’d probably be looking to go out early next year.”

A further funding round from venture capital investors, who have already put up $35.4 million, is a fallback option if the window for biotech IPO fund-raisings closes before then, he added.

Convergence’s backers include Apposite Capital, New Leaf and SV Life Sciences. GSK also retains an 18 percent stake in Convergence.

This article has been extracted from http://www.reuters.com, please click on this link to read the article in full http://www.reuters.com/article/2014/06/16/us-britain-biotech-ipos-idUSKBN0ER0UE20140616

Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:

ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.

With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.

comments powered by Disqus

Social Stream

Latest News

W1siziisijiwmtcvmdivmtuvmtyvntivmjuvnzkwl2n5ymvyigf0dgfja3muanbnil0swyjwiiwidgh1bwiilcizodb4mtawiyjdxq

UK threatened by serious cyber attacks every ...

2017-02-15 16:00:00 +0000

The security of the UK has been threatened by 188 serious cyber attacks in the last three months, a government security chief has said. National Cyber Security Centre (NCSC) Chief Executive Ciaran Martin told The Sunday Times that national security was put at risk by many of these attacks. Martin was speaking ahead of the official opening of the NCSC, which has been set up to protect critical services in the UK from such attacks and improve underlying i...

W1siziisijiwmtcvmdivmdgvmtavmzcvmzkvnjkyl0n5ymvyifnly3vyaxr5lmpwzyjdlfsiccisinrodw1iiiwimzgwedewmcmixv0

British cyber security workforce rises 163%

2017-02-08 10:00:00 +0000

Data from the UK has shown that the cyber security workforce has grown considerably over the past five years. According to a new report from cyber skills promotion network Tech Partnership, there are now 58,000 more workers in this industry – a rise of 163 per cent. It shows the growing importance of these professionals, with firms across a vast range of industries turning to cyber security specialists to safeguard their data. To collate the report, the...